| Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer (NCT00816413) | University of Nebraska | 2008-09-01 |
| A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS) (NCT00750334) | Genzyme, a Sanofi Company | 2008-09-01 |
| Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma (NCT00761722) | Celgene | 2008-08-12 |
| A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies (NCT00719836) | S*BIO | 2008-08-01 |
| Blood Samples From Patients on a Clinical Trial to CINV During HSCT (NCT00900068) | OHSU Knight Cancer Institute | 2008-08-01 |
| Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (NCT00614523) | Amgen | 2008-07-21 |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant (NCT00725062) | Masonic Cancer Center, University of Minnesota | 2008-06-01 |
| A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion (NCT00695396) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-06-01 |
| Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases (NCT00813501) | City of Hope Medical Center | 2008-06-01 |
| A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families (NCT00782145) | Tufts Medical Center | 2008-06-01 |
| An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS) (NCT01026376) | Janssen-Cilag Farmaceutica Ltda. | 2008-06-01 |
| LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) (NCT00691938) | Washington University School of Medicine | 2008-06-01 |
| Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia (NCT00607997) | Sunesis Pharmaceuticals | 2008-05-15 |
| Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome (NCT01546337) | Rennes University Hospital | 2008-05-01 |
| Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers (NCT00770419) | Rutgers, The State University of New Jersey | 2008-05-01 |
| Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (NCT00720850) | Technische Universität Dresden | 2008-04-01 |
| Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT00624936) | Ohio State University Comprehensive Cancer Center | 2008-04-01 |
| Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial (NCT00750009) | Case Comprehensive Cancer Center | 2008-04-01 |
| Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome (NCT00732316) | Asan Medical Center | 2008-04-01 |
| Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome (NCT00731328) | Asan Medical Center | 2008-04-01 |
| Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx) (NCT00700011) | Texas Oncology Cancer Center | 2008-03-01 |
| Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer (NCT00516503) | Alliance for Clinical Trials in Oncology | 2008-02-01 |
| Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts (NCT00624585) | H. Lee Moffitt Cancer Center and Research Institute | 2008-02-01 |
| Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS (NCT00744536) | Sunnybrook Health Sciences Centre | 2008-01-01 |
| Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant (NCT00513474) | Massachusetts General Hospital | 2008-01-01 |
| Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload (NCT00564941) | Novartis Pharmaceuticals | 2007-12-01 |
| Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT00516828) | NCIC Clinical Trials Group | 2007-11-27 |
| Investigation of the Cylex® ImmuKnow® Assay (NCT00569842) | Indiana University | 2007-11-01 |
| Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload (NCT00673608) | Novartis | 2007-11-01 |
| Studying Fentanyl in Patients With Cancer (NCT00899951) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-10-01 |
| Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes (NCT00361296) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-09-01 |
| Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer (NCT00555048) | Fred Hutchinson Cancer Center | 2007-09-01 |
| Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality. (NCT00812968) | Celgene | 2007-09-01 |
| A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes. (NCT00551291) | Hoffmann-La Roche | 2007-08-01 |
| Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes (NCT00493571) | M.D. Anderson Cancer Center | 2007-08-01 |
| Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer (NCT00499668) | Vanderbilt-Ingram Cancer Center | 2007-08-01 |
| A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies (NCT00569179) | Indiana University | 2007-08-01 |
| Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant (NCT00526292) | Memorial Sloan Kettering Cancer Center | 2007-08-01 |
| Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant (NCT00602446) | Masonic Cancer Center, University of Minnesota | 2007-08-01 |
| T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer (NCT00602693) | Masonic Cancer Center, University of Minnesota | 2007-07-23 |
| Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) (NCT00480987) | M.D. Anderson Cancer Center | 2007-07-01 |
| A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts (NCT00565656) | Centre Hospitalier Universitaire de Nice | 2007-07-01 |
| Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes (NCT00641030) | City of Hope Medical Center | 2007-07-01 |
| Safety, Tolerability, and Efficacy of Deferasirox in MDS (NCT00469560) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2007-06-01 |
| Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) (NCT00486720) | Merck Sharp & Dohme LLC | 2007-06-01 |
| Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers (NCT00619645) | University of California, Davis | 2007-06-01 |
| Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin (NCT00915811) | King's College Hospital NHS Trust | 2007-06-01 |
| A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) (NCT00531232) | Genzyme, a Sanofi Company | 2007-05-07 |
| Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes (NCT00503880) | University of Nebraska | 2007-05-07 |
| PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS (NCT00439673) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2007-05-01 |
| Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload (NCT00481143) | Novartis Pharmaceuticals | 2007-05-01 |
| Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (NCT00589563) | City of Hope Medical Center | 2007-05-01 |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases (NCT00376519) | Masonic Cancer Center, University of Minnesota | 2007-05-01 |
| Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer (NCT00787761) | Northside Hospital, Inc. | 2007-04-01 |
| Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant (NCT00898118) | European Working Group of MDS in Childhood | 2007-04-01 |
| Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) (NCT00472290) | Amgen | 2007-04-01 |
| An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS) (NCT01186939) | Celgene | 2007-04-01 |
| Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts (NCT00804050) | Fondazione Italiana Sindromi Mielodisplastiche-ETS | 2007-03-01 |
| Survey on QUality of Life In myeloDisplasia (SQUID) (NCT00967564) | Janssen-Cilag S.p.A. | 2007-03-01 |
| Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer (NCT00806767) | Institut Paoli-Calmettes | 2007-03-01 |
| Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases (NCT00438958) | The Canadian Blood and Marrow Transplant Group | 2007-03-01 |
| Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (NCT00451048) | National Cancer Institute (NCI) | 2007-02-01 |
| Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases (NCT00453206) | Wake Forest University Health Sciences | 2007-02-01 |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes (NCT00234000) | Jonsson Comprehensive Cancer Center | 2007-02-01 |
| Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome (NCT00513578) | The Vaccine Company | 2007-01-01 |
| Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment (NCT00499070) | University Hospital Freiburg | 2007-01-01 |
| Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases (NCT00424242) | Northwestern University | 2007-01-01 |
| Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant (NCT00900406) | Vanderbilt-Ingram Cancer Center | 2007-01-01 |
| Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant (NCT00964821) | City of Hope Medical Center | 2007-01-01 |
| Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants (NCT00899327) | Oxford University Hospitals NHS Trust | 2007-01-01 |
| Darbepoetin Alpha in Myelodysplastic Syndromes (MDS) (NCT00443339) | Groupe Francophone des Myelodysplasies | 2006-12-01 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS) (NCT00413114) | Gemin X | 2006-12-01 |
| T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant (NCT00651716) | Vanderbilt-Ingram Cancer Center | 2006-12-01 |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases (NCT00450983) | Fred Hutchinson Cancer Center | 2006-12-01 |
| A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid (NCT00418665) | Amgen | 2006-12-01 |
| Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease (NCT00423514) | Memorial Sloan Kettering Cancer Center | 2006-11-20 |
| Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) (NCT00406393) | Medical College of Wisconsin | 2006-11-01 |
| Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia (NCT00886496) | Enzon Pharmaceuticals, Inc. | 2006-11-01 |
| Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT00425477) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2006-11-01 |
| AVIDA The Vidaza® (Azacitidine) Patient Registry (NCT00481273) | Celgene | 2006-10-31 |
| Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes (NCT00045305) | Eastern Cooperative Oncology Group | 2006-10-24 |
| Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies (NCT00356928) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2006-10-01 |
| Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31] (NCT00424229) | Groupe Francophone des Myelodysplasies | 2006-10-01 |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma (NCT00398138) | Memorial Sloan Kettering Cancer Center | 2006-10-01 |
| Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents (NCT00321711) | Amgen | 2006-10-01 |
| Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes (NCT00398047) | Wake Forest University Health Sciences | 2006-09-01 |
| MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease (NCT00374296) | Mirati Therapeutics Inc. | 2006-09-01 |
| Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias (NCT00522990) | Astex Pharmaceuticals, Inc. | 2006-09-01 |
| Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes (NCT00379912) | Larry Cripe, MD | 2006-09-01 |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (NCT00454480) | The University of New South Wales | 2006-08-01 |
| A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes (NCT00384956) | Washington University School of Medicine | 2006-08-01 |
| Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies (NCT00544466) | City of Hope Medical Center | 2006-07-31 |
| A Phase II Study of Maintenance With Azacitidine in MDS Patients (NCT00446303) | Groupe Francophone des Myelodysplasies | 2006-07-01 |
| Sorafenib in Myelodysplastic Syndrome (NCT00510289) | Duke University | 2006-07-01 |
| Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes (NCT00382200) | Memorial Sloan Kettering Cancer Center | 2006-07-01 |
| Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant (NCT00410657) | Fred Hutchinson Cancer Center | 2006-07-01 |
| Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases (NCT00376922) | Wake Forest University Health Sciences | 2006-06-01 |
| Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer (NCT00827099) | Northside Hospital, Inc. | 2006-06-01 |
| An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia (NCT00346632) | Kyowa Kirin, Inc. | 2006-06-01 |
| Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer (NCT00085449) | Alliance for Clinical Trials in Oncology | 2006-05-01 |